N@N

Cobalis Corp.: Cobalis Confirms Funding for Operations and Initiation of Their PreHistin(R) "All Natural Allergy Relief(R)

^{Published on 2009-07-23 13:27:41, Last Modified on 2009-07-23 13:27:56 - Market Wire}
 

IRVINE, CA--(Marketwire - July 23, 2009) - Cobalis Corporation (PINKSHEETS: [ CLSC ]) is pleased to announce that additional funding has been raised from Cobalis investors and an international PreHistin® distribution partner to finance operations, marketing and video production of 30-, 60- and 120-second advertisements for their August 2009 TV and Internet video national advertising branding campaign for PreHistin®, "The World's FIRST Pre-Histamine®."

These funds were confirmed on July 9, 2009 as part of the requirement to remain in Chapter 11. Consequently, both motions to convert were withdrawn on July 13, 2009 by order of the court in Santa Ana, CA.

The planned national advertising campaign, "Stop Allergies BEFORE they Start®," furthers Cobalis' efforts to brand PreHistin® internationally on the Internet and through direct TV advertising. Cobalis continues to generate sales revenue at [ www.PreHistin.com ] and through its toll-free call center at: 1-877-4POLLEN. The PreHistin® retail store roll-out campaign is scheduled for 2010.

This important funding milestone furthers Cobalis' commitment to reorganize and emerge from Chapter 11, while continuing their international branding campaign strategy for PreHistin® as "the choice for all natural allergy relief®." The company continues to capitalize on its extensive and growing international patent portfolio, including two U.S. Patents #5,135,918 "Method for Decreasing Reaginic Antibody Levels" and #6,255,294 "Cyanocobalamin Treatment in Allergic Disease" and monetize their significant intellectual property.

ABOUT COBALIS CORP. -- PREHISTIN®

Cobalis Corp. is an [ over the counter pharmaceutical ] and nutraceutical company. Its flagship product PreHistin® is designed to prevent the primary causes of [ airborne allergies ].

PreHistin®, "The [ World's FIRST Pre-Histamine ]®," is the only Phase III clinically tested sublingual product fully patented for long term and daily use without a prescription to help relieve allergy sufferers from both indoor and outdoor allergens.

PreHistin® has shown in previous clinical studies the ability to modulate the body's level of immunoglobulin E (IgE), thus reducing the overproduction of histamines, the primary cause of airborne allergy symptoms. Studies have shown that the active ingredient in PreHistin®, an FDA safety approved 3.3 mg Cyanocobalamin (Vitamin B12) mega-dose sub-lingual lozenge, has essentially no risks or adverse side effects to the general population including sedation and drowsiness found in many allergy medications currently available.

For PreHistin® product information and ordering please visit at [ www.PreHistin.com ] or call toll free 1-877-4POLLEN. For additional company information please visit their website at [ www.Cobalis.com ]